Skip to main content
Premium Trial:

Request an Annual Quote

Diatech, Janssen Partner to Develop Molecular Diagnostics for Bladder Cancer

NEW YORK – Diatech Pharmacogenetics on Tuesday said it has established a partnership with Janssen Pharmaceutica centered on improving access to precision medicine for patients with bladder cancer.

Diatech is developing an in vitro diagnostic assay to guide the use of precision medicine therapies for patients with bladder cancer based on their individual genetic profile. The goal of the project is to facilitate precision medicine testing worldwide by developing a highly sensitive test that can complete analysis of genetic alterations in the cancer in three hours using real-time PCR. 

The Jesi, Italy-based company announced in April that it expects an investment from private equity firm TA Associates in Q2 2023 to support its efforts to expand into international markets.

Diatech markets a line of PCR-based oncology kits including the easyPGX to detect KRAS, NRAS, BRAF, and EGFR with a turnaround time of less than three hours.


The Scan

Cystatin C Plays Role in Immunosuppression, Cancer Immunotherapy Failure, Study Finds

A study in Cell Genomics provides insight into how glucocorticoids can lead to cancer immunotherapy failure via cystatin C production.

Aging, Species Lifespan Gene Expression Signatures Overlap

An Osaka Metropolitan University team reports in Nucleic Acids Research that transcriptional signatures of aging and maximum lifespan have similarities.

Splicing Subgroup Provides Protocols for Evaluating Splicing Variant Data

The group presents their approach on how to apply evidence codes to splicing predictions and other data in the American Journal of Human Genetics.

Single-Cell Transcriptomic Atlas of Mouse Cochlea to Aid Treatment Development

Researchers in PNAS conducted single-cell and single-nuclear sequencing of about 120,000 cells at three key timepoints in cochlear development to generate a transcriptomic atlas.